| 应用 |
A potent and selective CETP inhibitor. |
| 产品介绍 |
Anacetrapib (MK-0859)是一种有效的，选择性，可逆的rhCETP和突变CETP(C13S)抑制剂，IC50分别为7.9 nM和11.8 nM，提高HDL-C，降低LDL-C，不提高醛固酮和血压。Phase 3。 |
| 备注 |
Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
| 生化机理 |
Anacetrapib is a potent and selective CETP inhibitor for rhCETP and C13S CETP mutants with IC50 of 7.9 nM and 11.8 nM, respectively. |
| 别名 |
安塞曲匹;胆固醇脂转移蛋白阻滞剂;(4S,5R)-5-[3,5-双(三氟甲基)苯基]-3-({2-[4-氟-2-甲氧基-5-(丙-2-基)苯基]-5-(三氟甲基)苯基}甲基)-4-甲基-1,3-恶唑烷-2-酮;MK 0859;MK-0859;MK0859; (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one |
